JAK2
-
S*BIO to initiate global phase 3 clinical trials of its novel JAK2 inhibitor
S*BIO explores partnering opportunities for advancement of its JAK2 program.
JAK2 | 25 October 2011
-
S*BIO initiates phase 2 clinical trial of its JAK2 inhibitor
S*BIO Pte Ltd announced that it has dosed the first 10 patients in a phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the US and Canada for the treatment of advanced lymphoid malignancies. This multi-center, open-label, study is design…
JAK2 | 14 April 2011
-
S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors
S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively…
JAK2 | 19 May 2010
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
JAK2 | 09 December 2009
-
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors
S*BIO has announced that it has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals to develop and commercialize S*BIO’s JAK2 inhibitors, SB1518 and SB1578. Under the terms of the agreement, S*BIO i…
JAK2 | 08 January 2009
-
S*BIO Commences Phase 1 of Clinical Trial
Singapore-based company S*BIO has initiated phase 1 of the clinical trial for SB1518, a potent and orally-active Janus kinase 2 (JAK2) inhibitor. This is being carried out in medical centers in Australia for patients with chronic idiopathic myelo…
JAK2 | 04 December 2008
-
New Kit Measures JAK2 Phosphorylation
Invitrogen’s JAK2 (pYpY1007â„1008) phosphoELISA kit is a complete ELISA assay to rapidly, efficiently and quantitatively detect phosphorylated JAK2. Phosphorylation, or the addition of phosphate groups, is essential to the activation of many enzym…
JAK2 | 01 October 2008
-
Singapore company initiates Phase I clinical trials of SB1518
S*BIO has announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These comprise of ascending dose studies conducted at severa…
JAK2 | 22 September 2008
